Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P MALEK

Showing results (161-170 of 185) with videos related to

Pageof 19
Sort By:
JAMIA Open|April 26, 2021
Annotation and initial evaluation of a large annotated German oncological corpusMadeleine Kittner, Mario Lamping, Damian T Rieke, et al.
Nature Communications|February 12, 2024
The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinomaStephan Spahn, Fabian Kleinhenz, Ekaterina Shevchenko, et al.
Nature Medicine|May 24, 2016
A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancerDaniel Dauch, Ramona Rudalska, Giacomo Cossa, et al.
NPJ Precision Oncology|September 4, 2021
Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinomaMichael Bitzer, Stephan Spahn, Sepideh Babaei, et al.
Nature Medicine|September 14, 2014
In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancerRamona Rudalska, Daniel Dauch, Thomas Longerich, et al.
Cell|April 16, 2013
A Direct in vivo RNAi screen identifies MKK4 as a key regulator of liver regenerationTorsten Wuestefeld, Marina Pesic, Ramona Rudalska, et al.
Gastro Hep Advances|February 6, 2025
Adenosine Receptor 3 in Liver Cancer: Expression Variability, Epigenetic Modulation, and Enhanced Histone Deacetylase Inhibitor EffectsLouise Kaldjob-Heinrich, Sandro Nuciforo, Steffen Lemke, et al.
Plos One|June 7, 2018
Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantationJulia M Grottenthaler, Christoph R Werner, Martina Steurer, et al.
European Journal of Cancer (Oxford, England : 1990)|December 10, 2022
Germline findings in patients with advanced malignancies screened with paired blood-tumour testing for personalised treatment approachesCristiana Roggia, Sorin Armeanu-Ebinger, Axel Gschwind, et al.
Nature Cancer|February 5, 2022
LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancerRamona Rudalska, Jule Harbig, Marteinn T Snaebjornsson, et al.
Pageof 19

Showing results (161-170 of 185) with videos related to

Sort By:
Pageof 19
JAMIA Open|April 26, 2021
Annotation and initial evaluation of a large annotated German oncological corpusMadeleine Kittner, Mario Lamping, Damian T Rieke, et al.
Nature Communications|February 12, 2024
The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinomaStephan Spahn, Fabian Kleinhenz, Ekaterina Shevchenko, et al.
Nature Medicine|May 24, 2016
A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancerDaniel Dauch, Ramona Rudalska, Giacomo Cossa, et al.
NPJ Precision Oncology|September 4, 2021
Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinomaMichael Bitzer, Stephan Spahn, Sepideh Babaei, et al.
Nature Medicine|September 14, 2014
In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancerRamona Rudalska, Daniel Dauch, Thomas Longerich, et al.
Cell|April 16, 2013
A Direct in vivo RNAi screen identifies MKK4 as a key regulator of liver regenerationTorsten Wuestefeld, Marina Pesic, Ramona Rudalska, et al.
Gastro Hep Advances|February 6, 2025
Adenosine Receptor 3 in Liver Cancer: Expression Variability, Epigenetic Modulation, and Enhanced Histone Deacetylase Inhibitor EffectsLouise Kaldjob-Heinrich, Sandro Nuciforo, Steffen Lemke, et al.
Plos One|June 7, 2018
Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantationJulia M Grottenthaler, Christoph R Werner, Martina Steurer, et al.
European Journal of Cancer (Oxford, England : 1990)|December 10, 2022
Germline findings in patients with advanced malignancies screened with paired blood-tumour testing for personalised treatment approachesCristiana Roggia, Sorin Armeanu-Ebinger, Axel Gschwind, et al.
Nature Cancer|February 5, 2022
LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancerRamona Rudalska, Jule Harbig, Marteinn T Snaebjornsson, et al.
Pageof 19